HealthDay News — Half of adults who start semaglutide for weight loss discontinue within a year, according to a study presented at the annual meeting of the European Association for the Study of Diabetes, held from Sept. 15 to 19 in Vienna. Aurélie Mailhac, from Aarhus University in Denmark, and colleagues examined the likelihood of and factors associated with discontinuation of semaglutide for weight loss in Denmark. The analysis included 77,310 adults without diabetes initiating semaglutide for weight loss from Dec. 1, 2022, to Oct. 1, 2023. Younger users (risk ratio [RR], 1.48 for 18 to 30 years versus 45 to 60 years old) and men (RR, 1.12 versus women) had increased an likelihood of discontinuation. “These results are new and shed light on the reasons for high rates of early discontinuation of semaglutide for weight loss in a real-world setting,” lead author Reimar W. Thomsen, also from Aarhus University, said in a statement.